Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes

Huda Shafic Salman, Katie Tanaka, Joseph A. Sparano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this study was to determine the maximum tolerated dose (MTD) of infusional gemcitabine given in conjunction with intravenous (I.V.) cyclophosphamide, and to determine whether the regimen produced a response rate of at least 40% in patients with metastatic breast cancer who have been previously treated with taxanes. Patients received cyclophosphamide (600 mg/m2) I.V. followed immediately by gemcitabine (100, 150, or 200 mg/m2) given as a 24-hour infusion (every 3 weeks) using an accelerated dose-escalation schema. Dose-limiting toxicity was defined as a neutrophil nadir < 500/μL, platelet nadir < 50,000/μL, or ≥ grade 2 nonhematologic toxicity (≥ grade 3 toxicity during the standard dose-escalation portion of the study). Twelve patients received a total of 32 cycles of therapy. The MTD of gemcitabine was 150 mg/m2. Dose-limiting toxicities at 200 mg/m2 included neutropenia and mucositis. One patient with lymphangitic lung metastases had a partial response (8%; 95% confidence intervals: 0%, 23%). This patient developed grade 4 transaminase and total bilirubin elevation that occurred affer the sixth cycle of therapy. The study was terminated due to an insufficient number of responses. The MTD of gemcitabine given as a 24-hour infusion is 150 mg/m2 when used in conjunction with cyclophosphamide (600 mg/m2) every 3 weeks. This regimen is not likely to produce more than a 40% response rate in patients with metastatic breast cancer previously treated with taxanes.

Original languageEnglish (US)
Pages (from-to)299-303
Number of pages5
JournalClinical Breast Cancer
Volume2
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint

gemcitabine
Taxoids
Cyclophosphamide
Breast Neoplasms
Maximum Tolerated Dose
Mucositis
Transaminases
Neutropenia
Bilirubin
Neutrophils
Blood Platelets
Confidence Intervals
Neoplasm Metastasis
Lung

Keywords

  • Cyclophosphamide
  • Dose-limiting toxicity
  • Gemcitabine
  • Maximum tolerated dose

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. / Salman, Huda Shafic; Tanaka, Katie; Sparano, Joseph A.

In: Clinical Breast Cancer, Vol. 2, No. 4, 01.01.2002, p. 299-303.

Research output: Contribution to journalArticle

@article{c82a1c46a3c043a290982342bac2c973,
title = "Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes",
abstract = "The purpose of this study was to determine the maximum tolerated dose (MTD) of infusional gemcitabine given in conjunction with intravenous (I.V.) cyclophosphamide, and to determine whether the regimen produced a response rate of at least 40{\%} in patients with metastatic breast cancer who have been previously treated with taxanes. Patients received cyclophosphamide (600 mg/m2) I.V. followed immediately by gemcitabine (100, 150, or 200 mg/m2) given as a 24-hour infusion (every 3 weeks) using an accelerated dose-escalation schema. Dose-limiting toxicity was defined as a neutrophil nadir < 500/μL, platelet nadir < 50,000/μL, or ≥ grade 2 nonhematologic toxicity (≥ grade 3 toxicity during the standard dose-escalation portion of the study). Twelve patients received a total of 32 cycles of therapy. The MTD of gemcitabine was 150 mg/m2. Dose-limiting toxicities at 200 mg/m2 included neutropenia and mucositis. One patient with lymphangitic lung metastases had a partial response (8{\%}; 95{\%} confidence intervals: 0{\%}, 23{\%}). This patient developed grade 4 transaminase and total bilirubin elevation that occurred affer the sixth cycle of therapy. The study was terminated due to an insufficient number of responses. The MTD of gemcitabine given as a 24-hour infusion is 150 mg/m2 when used in conjunction with cyclophosphamide (600 mg/m2) every 3 weeks. This regimen is not likely to produce more than a 40{\%} response rate in patients with metastatic breast cancer previously treated with taxanes.",
keywords = "Cyclophosphamide, Dose-limiting toxicity, Gemcitabine, Maximum tolerated dose",
author = "Salman, {Huda Shafic} and Katie Tanaka and Sparano, {Joseph A.}",
year = "2002",
month = "1",
day = "1",
doi = "10.3816/CBC.2002.n.006",
language = "English (US)",
volume = "2",
pages = "299--303",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes

AU - Salman, Huda Shafic

AU - Tanaka, Katie

AU - Sparano, Joseph A.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The purpose of this study was to determine the maximum tolerated dose (MTD) of infusional gemcitabine given in conjunction with intravenous (I.V.) cyclophosphamide, and to determine whether the regimen produced a response rate of at least 40% in patients with metastatic breast cancer who have been previously treated with taxanes. Patients received cyclophosphamide (600 mg/m2) I.V. followed immediately by gemcitabine (100, 150, or 200 mg/m2) given as a 24-hour infusion (every 3 weeks) using an accelerated dose-escalation schema. Dose-limiting toxicity was defined as a neutrophil nadir < 500/μL, platelet nadir < 50,000/μL, or ≥ grade 2 nonhematologic toxicity (≥ grade 3 toxicity during the standard dose-escalation portion of the study). Twelve patients received a total of 32 cycles of therapy. The MTD of gemcitabine was 150 mg/m2. Dose-limiting toxicities at 200 mg/m2 included neutropenia and mucositis. One patient with lymphangitic lung metastases had a partial response (8%; 95% confidence intervals: 0%, 23%). This patient developed grade 4 transaminase and total bilirubin elevation that occurred affer the sixth cycle of therapy. The study was terminated due to an insufficient number of responses. The MTD of gemcitabine given as a 24-hour infusion is 150 mg/m2 when used in conjunction with cyclophosphamide (600 mg/m2) every 3 weeks. This regimen is not likely to produce more than a 40% response rate in patients with metastatic breast cancer previously treated with taxanes.

AB - The purpose of this study was to determine the maximum tolerated dose (MTD) of infusional gemcitabine given in conjunction with intravenous (I.V.) cyclophosphamide, and to determine whether the regimen produced a response rate of at least 40% in patients with metastatic breast cancer who have been previously treated with taxanes. Patients received cyclophosphamide (600 mg/m2) I.V. followed immediately by gemcitabine (100, 150, or 200 mg/m2) given as a 24-hour infusion (every 3 weeks) using an accelerated dose-escalation schema. Dose-limiting toxicity was defined as a neutrophil nadir < 500/μL, platelet nadir < 50,000/μL, or ≥ grade 2 nonhematologic toxicity (≥ grade 3 toxicity during the standard dose-escalation portion of the study). Twelve patients received a total of 32 cycles of therapy. The MTD of gemcitabine was 150 mg/m2. Dose-limiting toxicities at 200 mg/m2 included neutropenia and mucositis. One patient with lymphangitic lung metastases had a partial response (8%; 95% confidence intervals: 0%, 23%). This patient developed grade 4 transaminase and total bilirubin elevation that occurred affer the sixth cycle of therapy. The study was terminated due to an insufficient number of responses. The MTD of gemcitabine given as a 24-hour infusion is 150 mg/m2 when used in conjunction with cyclophosphamide (600 mg/m2) every 3 weeks. This regimen is not likely to produce more than a 40% response rate in patients with metastatic breast cancer previously treated with taxanes.

KW - Cyclophosphamide

KW - Dose-limiting toxicity

KW - Gemcitabine

KW - Maximum tolerated dose

UR - http://www.scopus.com/inward/record.url?scp=0036194991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036194991&partnerID=8YFLogxK

U2 - 10.3816/CBC.2002.n.006

DO - 10.3816/CBC.2002.n.006

M3 - Article

C2 - 11899362

AN - SCOPUS:0036194991

VL - 2

SP - 299

EP - 303

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -